Abstract
The role for PET with fludeoxyglucose F 18 (18F-FDG PET)/computed tomography (CT) in the management of pediatric sarcomas continues to be controversial. The literature supports a role for PET/CT in the staging and surveillance of certain specific pediatric sarcoma subtypes; however, the data are less clear regarding whether PET/CT can be used as a biomarker for prognostication. Despite the interest in using this imaging modality in the management of pediatric sarcomas, most studies are limited by retrospective design and small sample size. Additional data are necessary to fully understand how best to use 18F-FDG PET/CT in pediatric sarcoma management.
Original language | English (US) |
---|---|
Pages (from-to) | 333-347 |
Number of pages | 15 |
Journal | PET Clinics |
Volume | 15 |
Issue number | 3 |
DOIs | |
State | Published - Jul 2020 |
Keywords
- Ewing sarcoma
- F-FDG PET/CT
- Non-rhabdomyosarcoma soft tissue sarcoma
- Osteosarcoma
- Rhabdomyosarcoma
ASJC Scopus subject areas
- Radiation
- Radiology Nuclear Medicine and imaging